Sun Pharma Advanced Research Company (SPARC) has entered into an agreement with Bioprojet SCR (Bioprojet) to exclusively acquire Bioprojet’s rights to the investigational medicinal product SCD-044. SPARC and Bioprojet co-owned all SCD-044 related IP, developed through a research collaboration targeting Sphingosine -1-Phosphate Receptors (S1PR) to treat various autoimmune disorders.
The acquisition includes full assignment of all patents and patent applications owned or controlled by Bioprojet related to SCD-044. Under the terms of the agreement, Bioprojet is eligible to receive milestones and royalties on net sales of SCD-044
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 435.70 |
| Indegene | 486.80 |
| CMS Info Systems | 318.00 |
| JITF Infralogistics | 338.00 |
| Sagility | 42.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: